Product Name | Bml 259 |
Description |
CDK5, p25 kinase inhibitor |
Purity | >98% (TLC) |
CAS No. | 267654-00-2 |
Molecular Formula | C14H16N2OS |
Molecular Weight | 260.4 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in DMSO (30 mg/ml), dimethyl formamide (30 mg/ml) or 100% ethanol (0.25 mg/ml) |
Source | Synthetic |
Appearance | White solid |
SMILES | CC(C)C1=CN=C(S1)NC(=O)CC2=CC=CC=C2 |
InChI | InChI=1S/C14H16N2OS/c1-10(2)12-9-15-14(18-12)16-13(17)8-11-6-4-3-5-7-11/h3-7,9-10H,8H2,1-2H3,(H,15,16,17) |
InChIKey | IGRZXNLKVUEFDM-UHFFFAOYSA-N |
Safety Phrases |
Classification: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
Cite This Product | Bml 259 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-435) |
Alternative Names | N-(5-Isopropylthiazol-2-yl)phenylacetamide |
Research Areas | Apoptosis, Cancer, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors |
PubChem ID | 16760027 |
Scientific Background | Bml 259 is a potent inhibitor of cyclin-dependent kinase 5 (Cdk5)/p25, with additional inhibitory activity against Cdk2/cyclin E. Cdk5 is a critical regulator of neuronal development, synaptic function, and neurodegeneration. Aberrant activation of Cdk5, particularly through its association with p25, has been implicated in tau hyperphosphorylation and neuronal death in Alzheimer’s disease. Bml 259 is used in neuroscience to explore the pathological role of Cdk5/p25 signaling and to evaluate neuroprotective strategies targeting kinase dysregulation. |
References | 1. Kaźmierczak A., Czapski G.A., Adamczyk A., Gajkowska B., & Strosznajder J.B. (2011) Neurochem. Int. 58(2): 206–214. |
Reviews
There are no reviews yet.